This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Morse, G. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Morse, G. D.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, August 2005, p. 3373-3381, Vol. 49, No. 8
0066-4804/05/$08.00+0     doi:10.1128/AAC.49.8.3373-3381.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.

Amprenavir and Efavirenz Pharmacokinetics before and after the Addition of Nelfinavir, Indinavir, Ritonavir, or Saquinavir in Seronegative Individuals

Gene D. Morse,1,7* Susan Rosenkranz,2,7 Michael F. Para,3,7 Yoninah Segal,2,7 Robin DiFrancesco,1,7 Elizabeth Adams,4 Barbara Brizz,7,8 Kevin E. Yarasheski,5,7 Richard C. Reichman,6,7 the ACTG 5043 Protocol Team

University at Buffalo, SUNY, Amherst, New York,1 Harvard University, Boston, Massachusetts,2 Ohio State University, Columbus, Ohio,3 Division of AIDS, Bethesda, Maryland,4 Washington University, St. Louis, Missouri,5 University of Rochester, Rochester, New York,6 Social and Scientific Systems, Inc., Silver Spring, Maryland,7 Adult AIDS Clinical Trials Group (ACTG), NIAID, Bethesda, Maryland8

Received 3 November 2004/ Returned for modification 31 December 2004/ Accepted 25 April 2005

Adult AIDS Clinical Trials Group 5043 examined pharmacokinetic (PK) interactions between amprenavir (APV) and efavirenz (EFV) both by themselves and when nelfinavir (NFV), indinavir (IDV), ritonavir (RTV), or saquinavir (SQV) is added. A PK study was conducted after the administration of single doses of APV (day 0). Subjects (n = 56) received 600 mg of EFV every 24 h (q24h) for 10 days and restarted APV with EFV for days 11 to 13 with a PK study on day 14. A second protease inhibitor (PI) (NFV, 1,250 mg, q12h; IDV, 1,200 mg, q12h; RTV, 100 mg, q12h; or SQV, 1,600 mg, q12h) was added to APV and EFV on day 15, and a PK study was conducted on day 21. Controls continued APV and EFV without a second PI. Among subjects, the APV areas under the curve (AUCs) on days 0, 14, and 21 were compared using the Wilcoxon signed-rank test. Ninety-percent confidence intervals around the geometric mean ratios (GMR) were calculated. APV AUCs were 46% to 61% lower (median percentage of AUC) with EFV (day 14 versus day 0; P values of <0.05). In the NFV, IDV, and RTV groups, day 21 APV AUCs with EFV were higher than AUCs for EFV alone. Ninety-percent confidence intervals around the GMR were 3.5 to 5.3 for NFV (P < 0.001), 2.8 to 4.5 for IDV (P < 0.001), and 7.8 to 11.5 for RTV (P = 0.004). Saquinavir modestly increased the APV AUCs (GMR, 1.0 to 1.4; P = 0.106). Control group AUCs were lower on day 21 compared to those on day 14 (GMR, 0.7 to 1.0; P = 0.042). African-American non-Hispanics had higher day 14 efavirenz AUCs than white non-Hispanics. We conclude that EFV lowered APV AUCs, but nelfinavir, indinavir, or ritonavir compensated for EFV induction.

* Corresponding author. Mailing address: Adult ACTG Pharmacology Support Laboratory, Pharmacotherapy Research Center, Department of Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, 317 Hochstetter Hall, University at Buffalo, Amherst, NY 14260. Phone: (716) 645-2828, ext. 252. Fax: (716) 645-2886. E-mail: emorse{at}buffalo.edu.

Antimicrobial Agents and Chemotherapy, August 2005, p. 3373-3381, Vol. 49, No. 8
0066-4804/05/$08.00+0     doi:10.1128/AAC.49.8.3373-3381.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Shou, M., Hayashi, M., Pan, Y., Xu, Y., Morrissey, K., Xu, L., Skiles, G. L. (2008). Modeling, Prediction, and in Vitro in Vivo Correlation of CYP3A4 Induction. Drug Metab. Dispos. 36: 2355-2370 [Abstract] [Full Text]  
  • DeJesus, E., Piliero, P. J., Summers, K., Wire, M. B., Stein, D. S., Masterman, A., Lou, Y., Min, S. S., Shelton, M. J. (2006). Interaction between Fosamprenavir, with and without Ritonavir, and Nevirapine in Human Immunodeficiency Virus-Infected Subjects.. Antimicrob. Agents Chemother. 50: 3157-3159 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»